Bosentan in pulmonary hypertension secondary to left heart failure

References

• McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005;7:710–21
   PubMed Web of Science ®Google Scholar
• Drechsler K, Dietz R, Klein H, et al. Euro heart failure survey. Medical treatment not in line with current guidelines. Z Kardiol 2005;94:510–5
   Google Scholar
• Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623–6
   Google Scholar
• Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24: 442–63
   Google Scholar
• Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 2006;97:13F–25F
   Google Scholar
• Formiga F, Chivite D, Manito N, et al. One-year follow-up of heart failure patients after their first admission. Q J Med 2004;97:81–6
   Google Scholar
• Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137:352–60
   PubMed Web of Science ®Google Scholar
• Copeland JG, Emery RW, Levinson MM, et al. Selection of patients for cardiac transplantation. Circulation 1987;75:2–9
   PubMed Web of Science ®Google Scholar
• Moller JE, Hillis GS, Oh JK, et al. Prognostic importance of secondary pulmonary hypertension after acute myocardial infarction. Am J Cardiol 2005;96:199–203
   PubMed Web of Science ®Google Scholar
• Abramson SV, Burke JF, Kelly Jr JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992;116:888–95
   PubMed Web of Science ®Google Scholar
• Enriquez-Sarano M, Rossi A, Seward JB, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997;29:153–9
   PubMed Web of Science ®Google Scholar
• Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102:1718–23
   Google Scholar
• Deuchar GA, Docherty A, MacLean MR, et al. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Br J Pharmacol 2002;135:1060–8
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61: 227–37
   Google Scholar
• Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993;92:398–403
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Yanagisawa M, Kimura S, et al. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol 1988;255:H970–H973
   PubMed Web of Science ®Google Scholar
• Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209–15
   PubMed Web of Science ®Google Scholar
• Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999;100: 5–8
   Google Scholar
• Parker JD, Thiessen JJ. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 2004;286:H1141–H1145
   PubMed Web of Science ®Google Scholar
• Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Ann Rev Pharmacol Toxicol 2007;47:731–59
   Google Scholar
• Luchner A, Jougasaki M, Friedrich E, et al. Activation of cardio-renal and pulmonary tissue endothelin-1 in experimental heart failure. Am J Physiol Regul Integr Comp Physiol 2000;279: R974–R979
   PubMed Web of Science ®Google Scholar
• Pieske B, Beyermann B, Breu V, et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 1999;99: 1802–9
   PubMed Web of Science ®Google Scholar
• Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633–41
   PubMed Web of Science ®Google Scholar
• Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573–9
   PubMed Web of Science ®Google Scholar
• Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension [The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology]. Eur Heart J 2004;25:2243–78
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S–12S
   Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119–23
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 2002;346: 896–903
   PubMed Web of Science ®Google Scholar
• Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006;36(Suppl 3):54–61
   PubMedGoogle Scholar
• Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005;98:147–51
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S–24S
   Google Scholar
• Kobayashi T, Miyauchi T, Sakai S, et al. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol 1999;276: H1197–H1206
   PubMed Web of Science ®Google Scholar
• Hocher B, George I, Rebstock J, et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999;33:816–22
   PubMed Web of Science ®Google Scholar
• Krum H, Goldsmith R, Wilshire-Clement M, et al. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75:1282–3
   Google Scholar
• Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality [CONSENSUS Trial Study Group]. Circulation 1990;82:1730–6
   PubMed Web of Science ®Google Scholar
• Sutsch G, Bertel O, Rickenbacher P, et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol 2000;85: 973–6
   PubMed Web of Science ®Google Scholar
• Belloni AS, Rossi GP, Andreis PG, et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996;27:1153–9
   PubMed Web of Science ®Google Scholar
• Cleland JG, Dargie HJ, Hodsman GP, et al. Captopril in heart failure. A double blind controlled trial. Br Heart J 1984;52: 530–5
   Google Scholar